Candice Jamois

747 total citations
30 papers, 374 citations indexed

About

Candice Jamois is a scholar working on Oncology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Candice Jamois has authored 30 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Genetics and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Candice Jamois's work include Chronic Lymphocytic Leukemia Research (8 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Lymphoma Diagnosis and Treatment (8 papers). Candice Jamois is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Lymphoma Diagnosis and Treatment (8 papers). Candice Jamois collaborates with scholars based in Switzerland, United Kingdom and United States. Candice Jamois's co-authors include Ekaterina Gibiansky, Leonid Gibiansky, Norbert Frey, Christian Klein, Tina Nielsen, David Carlile, Christophe Schmitt, Ludger Banken, Patricia Sanwald Ducray and Xavier Liogier D’ardhuy and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Candice Jamois

28 papers receiving 367 citations

Peers

Countries citing papers authored by Candice Jamois

Since Specialization

Citations

This map shows the geographic impact of Candice Jamois's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Candice Jamois with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Candice Jamois more than expected).

Fields of papers citing papers by Candice Jamois

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Candice Jamois. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Candice Jamois. The network helps show where Candice Jamois may publish in the future.

Co-authorship network of co-authors of Candice Jamois

This figure shows the co-authorship network connecting the top 25 collaborators of Candice Jamois. A scholar is included among the top collaborators of Candice Jamois based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Candice Jamois. Candice Jamois is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL 2025 ·Clinical Pharmacology & Therapeutics ·Candice Jamois, David C. Turner, Leonid Gibiansky, (unknown), (unknown), Leonardo Pereira, Linda Lundberg, Elena Guerini, David Carlile, James Relf, Michael C. Wei, Antonia Kwan, Nicolas Frey, Susan Grange	1
2	Enhancing Severe Neutropenia Prediction: PKPD ‐Informed Labeling for Machine Learning Models Trained on Real‐World Data 2025 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), Elif Özkırımlı, Stefanie Bendels, Candice Jamois, (unknown), Dirk Fey, Kimmo Porkka, Oscar Brück, Ken Wang	0
3	Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients 2024 ·Blood ·Candice Jamois, Koorosh Korfi, Sylvia Herter, (unknown), (unknown), Marie-Hélène Wasmer, Isabel Prieto, Heather Hinton, Wouter H. P. Driessen, (unknown), (unknown), (unknown), Natalie Dimier, Katharina Lechner	0
4	First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations. 2024 ·Journal of Clinical Oncology ·Timothy A. Yap, Nehal J. Lakhani, Amita Patnaik, (unknown), Martin Gutierrez, Kathleen N. Moore, Benedito A. Carneiro, John L. Hays, Marilyn Huang, Patricia LoRusso, Andrew A. Wylie, (unknown), (unknown), Erica R. Tobin, Oliver Krieter, Daniela Schmid, Sophia M. Blake, Max Dieterich, Candice Jamois, Patricia M. Harris	9
5	Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers 2024 ·Clinical Pharmacology & Therapeutics ·Sébastien Benzekry, (unknown), (unknown), Abdessamad El Kaoutari, Bruno Gomes, Martin Stern, Aleš Neubert, René Bruno, François Mercier, (unknown), (unknown), Candice Jamois	6
6	Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1 2022 ·The AAPS Journal ·(unknown), Valeria Nicolini, Linda Fahrni, Inja Waldhauer, Antje‐Christine Walz, Candice Jamois, Stephen C. Fowler, (unknown), Christian Klein, Pablo Umaña, Lena E. Friberg, Nicolas Frances	3
7	Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis 2022 ·Clinical and Translational Science ·Candice Jamois, Leonid Gibiansky, (unknown), Melissa Cheu, Patricia B. Lehane, Pooneh Pordeli, (unknown), Jacques Gaudreault	3
8	The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study 2021 ·Blood Advances ·John Mascarenhas, Francesco Passamonti, Kate Burbury, Tarec Christoffer El‐Galaly, Aaron T. Gerds, Vikas Gupta, Brian Higgins, (unknown), Candice Jamois, Bruno Kovic, Ling‐Yuh Huw, (unknown), Margherita Maffioli, Ruben A. Mesa, Jeanne Palmer, Marta Bellini, David M. Ross, Alessandro M. Vannucchi, Abdulraheem Yacoub	16
9	Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study 2019 ·British Journal of Clinical Pharmacology ·Ekaterina Gibiansky, Leonid Gibiansky, (unknown), Nicolas Frey, Michael Brewster, Günter Fingerle‐Rowson, Candice Jamois	7
10	Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy 2019 ·British Journal of Clinical Pharmacology ·Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, (unknown), (unknown), Guillaume Cartron, Robert Marcus, Wolfgang Hiddemann, John F. Seymour, Jonathan C. Strefford, Chantal E. Hargreaves, Georgina Meneses‐Lorente, Nicolas Frey, Günter Fingerle‐Rowson	6
11	Greater Efficacy and Potency of Obinutuzumab Compared with Rituximab in Chronic Lymphocytic Leukemia Patients Confirmed By a Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Model 2017 ·Blood ·Kubra Kamisoglu, Alex Phipps, Candice Jamois, (unknown), Georgina Meneses‐Lorente, Günter Fingerle‐Rowson, Jonathan Wagg, Donald E. Mager	6
12	Pharmacokinetics of obinutuzumab in Chinese patients with B‐cell lymphomas 2017 ·British Journal of Clinical Pharmacology ·(unknown), Yan Qin, Jun Zhu, Yuqin Song, Zhixiang Shen, Xin Du, Candice Jamois, Michael Brewster, Yuankai Shi, Jun Yi Shi	6
13	Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline 2016 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), Anton Forsberg, Stephane Navé, Per Stenkrona, Nicholas Seneca, Andrea Varrone, Robert A. Comley, Patrik Fazio, Candice Jamois, Ryuji Nakao, (unknown), Nabil Al‐Tawil, (unknown), Christer Halldin, Niels Andreasen, Benedicte Ricci	21
14	First-in-man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin 2015 ·Journal of Cardiovascular Pharmacology ·Christophe Schmitt, Markus Abt, (unknown), Dorothée Kling, Candice Jamois, Eginhard Schick, Corinne Solier, Renée Benghozi, Jacques Gaudreault	43
15	Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non‐Hodgkin's Lymphoma and Exposure–Response in CLL 2014 ·CPT Pharmacometrics & Systems Pharmacology ·Ekaterina Gibiansky, Leonid Gibiansky, David Carlile, Candice Jamois, (unknown), Norbert Frey	75
16	The Effect of Aleglitazar on the Pharmacokinetics and Pharmacodynamics of S- and R-Warfarin in Healthy Male Subjects 2013 ·Journal of Cardiovascular Pharmacology ·Patricia Sanwald Ducray, Candice Jamois, Ludger Banken	3
17	Pharmacokinetics, Pharmacodynamics, and Tolerability of Aleglitazar in Patients With Type 2 Diabetes: Results From a Randomized, Placebo-Controlled Clinical Study 2010 ·Clinical Pharmacology & Therapeutics ·Patricia Sanwald Ducray, Xavier Liogier D’ardhuy, Candice Jamois, Ludger Banken	26
18	Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers 2009 ·PubMed ·Candice Jamois, Myriam Riek, Christophe Schmitt	9
19	CLINICAL STUDY: Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate‐dependent HIV‐negative patients on stable methadone maintenance therapy 2009 ·Addiction Biology ·Candice Jamois, Patrick F. Smith, (unknown), Myriam Riek, (unknown), Christophe Schmitt, Peter N. Morcos, Xiaoping Zhang	12
20	Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2 2004 ·Cancer Chemotherapy and Pharmacology ·Candice Jamois, Emmanuelle Comets, (unknown), (unknown), Robert Farinotti, Laurence Bonhomme‐Faivre	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact